140 related articles for article (PubMed ID: 10146352)
1. Immunologic monitoring during OKT3 therapy.
Chatenoud L
Clin Transplant; 1993 Aug; 7(4 Pt 2):422-30. PubMed ID: 10146352
[TBL] [Abstract][Full Text] [Related]
2. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
[TBL] [Abstract][Full Text] [Related]
3. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
Chatenoud L; Bach JF
Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
[TBL] [Abstract][Full Text] [Related]
4. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
[TBL] [Abstract][Full Text] [Related]
5. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3.
Chatenoud L; Baudrihaye MF; Chkoff N; Kreis H; Goldstein G; Bach JF
J Immunol; 1986 Aug; 137(3):830-8. PubMed ID: 3487589
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to OKT3 and methods for monitoring.
Schroeder TJ; Hariharan S; First MR
Transplant Proc; 1993 Apr; 25(2 Suppl 1):77-80. PubMed ID: 8465433
[TBL] [Abstract][Full Text] [Related]
7. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
[TBL] [Abstract][Full Text] [Related]
8. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
Bonnefoy-Berard N; Revillard JP
J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
11. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
[No Abstract] [Full Text] [Related]
12. OKT3-associated adverse reactions: mechanistic basis and therapeutic options.
Suthanthiran M; Fotino M; Riggio RR; Cheigh JS; Stenzel KH
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):39-44. PubMed ID: 2530898
[TBL] [Abstract][Full Text] [Related]
13. Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody.
Baudrihaye MF; Chatenoud L; Kreis H; Goldstein G; Bach JF
Eur J Immunol; 1984 Aug; 14(8):686-91. PubMed ID: 6381066
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.
Jaffers GJ; Fuller TC; Cosimi AB; Russell PS; Winn HJ; Colvin RB
Transplantation; 1986 May; 41(5):572-8. PubMed ID: 3085297
[TBL] [Abstract][Full Text] [Related]
15. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
Colvin RB; Preffer FI
Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
[TBL] [Abstract][Full Text] [Related]
16. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
18. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients.
Carreno M; Yang WC; Esquenazi V; Fuller L; Burke G; Milgrom M; Roth D; Ranjan D; Miller J
Transplantation; 1990 Feb; 49(2):408-15. PubMed ID: 1689519
[TBL] [Abstract][Full Text] [Related]
19. Cross-species reactivity of the anti-idiotype anti-OKT3 cascade between mice and humans.
Carreno M; Fuller L; Zucker K; Yang WC; Burke G; Nery J; Gomez C; Esquenazi V; Miller J
Hum Immunol; 1992 Apr; 33(4):249-58. PubMed ID: 1386353
[TBL] [Abstract][Full Text] [Related]
20. Prediction of successful allograft rejection retreatment with OKT3.
Legendre C; Kreis H; Bach JF; Chatenoud L
Transplantation; 1992 Jan; 53(1):87-90. PubMed ID: 1733090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
